摘要
目的:评价通络明目胶囊治疗糖尿病视网膜病变的有效性和安全性。方法:采用平行对照、随机、双盲临床试验方法,将146例受试者随机分为试验组和对照组,分别服用通络明目胶囊和羟苯磺酸钙胶囊治疗,疗程均为12周。结果:疾病综合疗效试验组为73.91%,对照组为72.31%;中医证候疗效试验组为89.86%;对照组为73.85%。2组比较疾病综合疗效差异无统计学意义(P>0.05)。结论:通络明目胶囊治疗糖尿病视网膜病变疗效与羟苯磺酸钙胶囊相当,且不良反应发生率低。
Objective： To evaluate the safety and effectiveness of TongLuo MingMu capsule for the treatment of diabetic retinopathy （DR）. Method： All 146 patients were randomized into the experiment group and the control group through parallel controlled, randomized, double-blind clinical trial. Both groups took TongLuo MingMu capsule and calcium dobesilate capsule respectively, the therapy lasted 12 weeks. Result： Comprehensive effect of the experiment group was 73.91%, higher than 72.31% of the control group; TCM effects of both groups were 89.86% and 73.85%. The difference had no statistical meaning between both groups in comprehensive effects of the disease （P〉0.05）. Conclusion： Curative effects of TongLuo MingMu capsule are notable in treating DR, similar to calcium dobesilate capsule but with lower incidence of adverse reaction.
出处
《西部中医药》
2013年第11期88-90,共3页
Western Journal of Traditional Chinese Medicine
